FDA Approves neffy® (epinephrine nasal spray) Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
ARS Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approved neffy® (epinephrine nasal spray) 2mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30kg (66lbs).
- The approval represents the first significant innovation in the delivery of epinephrine in more than 35 years and is the first and only needle-free treatment option for patients and families living with severe allergic reactions.
- Type I allergic reactions, including those caused by food, medications, and insect bites, can lead to lifethreatening anaphylaxis and result in an estimated 500,000 emergency room (ER) visits each year, with nearly 60% of such patients reported to not have received epinephrine prior to visiting the ER.
Source: ARS Pharmaceuticals, Inc.
